Pharmacyclics Outperformed Other Biotechs In June With A 74% Gain

July 1, 2012

June was a great month for health stocks – and biotechs in particular – with seven stocks gaining more than 40% over the month. The biggest winner was Pharmacyclics, which rose 74% on the prospects for its ibrutinib treatment for chronic lymphocytic leukemia. According to Needham analyst Alan Carr, CLL patients [...]

Comments are closed.